The literature has reported the weight loss effects of GLP-1-based therapies for individuals with obesity due to MC4R pathway mutations [16], and GLP-1 agonists might be an effective option in managing hypothalamic obesity. The gene discussed is GLP1R; the disease is obesity disorder.